News | Molecular Imaging | July 16, 2015

Trio of European Health Centers Upgrading to Elekta's Leksell Gamma Knife Icon

System integrates advanced motion management, dose delivery and imaging technologies for cranial radiosurgery

Elekta, Leksell Gamma Knife Icon, European health centers, upgrade

July 16, 2015 -- Three foremost medical centers in the United Kingdom and Germany have ordered and are now planning upgrades to Elekta's latest generation stereotactic radiosurgery system for the brain, Leksell Gamma Knife Icon. The centers are: University Medical Centre Mannheim (UMC, Mannheim, Germany); Bristol Gamma Knife Centre, University Hospitals Bristol NHS Foundation Trust (Bristol, U.K.); and The Leeds Gamma Knife Centre at St James's Institute of Oncology (Leeds, U.K.).

Leksell Gamma Knife Icon integrates advanced motion management, dose delivery and imaging technologies, enabling clinicians to treat a wider variety of tumor types and sizes. The system provides caregivers increased flexibility in how radiosurgery is delivered, by allowing doctors to choose either frame-based or frameless methods to immobilize the patient's head, in addition to the option to perform the treatment in a single session or multiple sessions. Icon also permits physicians to choose the degree of precision needed for each patient case - ranging from traditional high radiosurgery accuracy to ultra-precise microradiosurgery.

The ability to deliver multi-fraction Gamma Knife radiosurgery to spare organs-at-risk was important to clinicians at University Medical Centre Mannheim, according to Frederik Wenz, M.D., professor and chairman, Department of Radiation Oncology at UMC.

"The steep dose gradients and mechanical stability offered by Gamma Knife Icon allow sparing of normal tissue adjacent to the target," he said. "In clinical situations with sensitive structures within the target volume, sparing of organs-at-risk can only be achieved by fractionation [i.e., multiple sessions]. By fractionating the dose, we can use Icon in many clinical scenarios in which the tumor is infiltrating normal tissue."

Wenz anticipates treating the first patients with Gamma Knife Icon in late August.

Alison Cameron, M.D., clinical lead for the Bristol Gamma Knife, said: "Icon will allow Bristol to offer an intracranial stereotactic service without any compromises. The system has the flexibility to ensure that the patient receives the level of radiosurgery that they require clinically, whilst optimizing their experience through flexibility in immobilization, scheduling and treatment. This will lead to increased efficiency with improved quality, a truly transformational service development."

The team in Bristol expect to treat the first patient in September.

At The Leeds Gamma Knife Centre, Paul Hatfield, M.D., consultant clinical oncologist, observes that the frameless immobilization and accurate intrafraction monitoring of patient position are particularly valuable features of Icon.

"These features will enable fractionated treatment for targets that would normally be too large to treat, or where dose reductions would typically be required, for safety reasons, that could potentially compromise treatment effect," Hatfield said. "The cone beam CT [computed tomography] also will allow confirmation of setup, which is an important part of modern radiotherapy. All of these benefits combined will undoubtedly enhance the patient experience."

The Gamma Knife Icon system is expected to be operational at The Leeds Gamma Knife Centre by the end of 2015.

For more information: www.elekta.com

Related Content

Sponsored Content | Videos | Radiation Therapy | January 18, 2019
Join Chris Toth, president of Varian’s Oncology Systems business, for a look at product introductions for 2018 plus
MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
RayStation 8B Released With Machine Learning Applications for Treatment Planning
Technology | Treatment Planning | December 27, 2018
RaySearch Laboratories released RayStation 8B, the latest version of the radiation therapy treatment planning system (...
Axillary Radiotherapy and Lymph Node Surgery Yield Comparable Outcomes for Breast Cancer
News | Radiation Therapy | December 18, 2018
Early-stage breast cancer patients with cancer detected in a sentinel lymph node biopsy had comparable 10-year...
RaySearch Developing RayCommand Treatment Control System for U.K. Proton Therapy Facility
Technology | Radiation Therapy | December 10, 2018
RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Sponsored Content | Videos | Radiation Oncology | November 30, 2018
Accuray's philosophy is to personalize treatments to exactly fit the patient.